Fairvalue-Calculator Fairvalue-Calculator
EN DE

Choong Ang Vaccine Laboratory Co (072020) Fair Value & Analysis

Healthcare · KR · Market cap 91.3B KRW

Price9,200 KRW
Fair Value7,741 KRW
Upside-15.9%
Quality95/100
Evidence: High Range 5,689 KRW – 9,793 KRW

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Choong Ang Vaccine Laboratory Co (072020) currently trades at 9,200 KRW, while our model-based Fair Value estimate is 7,741 KRW — implying the stock looks roughly 15.9% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Choong Ang Vaccine Laboratory Co., Ltd. engages in the research, development, manufacturing, and sale of animal vaccines in South Korea, Asia, Africa, and the United States. It offers swine, poultry, cattle, canine, feline, wild boar, and raccoon vaccines under the SuiShot, PoulShot, BoviShot, CaniShot, and FeliShot brands. The company was founded in 1968 and is headquartered in Daejeon, South Korea.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is Choong Ang Vaccine Laboratory Co (072020) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 7,741 KRW versus a price of 9,200 KRW — about −16% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 072020?
Our 21-model fair value for Choong Ang Vaccine Laboratory Co is 7,741 KRW (as of Jun 24, 2026), built from audited fundamentals. The current price is 9,200 KRW.
What is the quality score of 072020?
Choong Ang Vaccine Laboratory Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.